Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Rybak

Showing results (101-110 of 531) with videos related to

Pageof 54
Sort By:
Antimicrobial Agents and Chemotherapy|June 25, 2004
In vitro activities of a novel cephalosporin, CB-181963 (CAB-175), against methicillin-susceptible or -resistant Staphylococcus aureus and glycopeptide-intermediate susceptible staphylococciVanthida Huang, William J Brown, Michael J Rybak
Infection Control and Hospital Epidemiology|March 8, 2013
Comparative epidemiology of bacteremia due to methicillin-resistant Staphylococcus aureus between older and younger adults: a propensity score analysisRavina Kullar, Michael J Rybak, Keith S Kaye
Antimicrobial Agents and Chemotherapy|February 16, 2011
Impact of dose de-escalation and escalation on daptomycin's pharmacodynamics against clinical methicillin-resistant Staphylococcus aureus isolates in an in vitro modelCeline Vidaillac, Molly E Steed, Michael J Rybak
Antimicrobial Agents and Chemotherapy|October 6, 2010
Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetationsMolly E Steed, Celine Vidaillac, Michael J Rybak
International Journal of Antimicrobial Agents|March 30, 2010
In vitro evaluation of ceftaroline alone and in combination with tobramycin against hospital-acquired meticillin-resistant Staphylococcus aureus (HA-MRSA) isolatesCéline Vidaillac, Steve N Leonard, Michael J Rybak
Antimicrobial Agents and Chemotherapy|November 26, 2003
Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetationsRaymond Cha, William J Brown, Michael J Rybak
Antimicrobial Agents and Chemotherapy|November 30, 2011
Evaluation of telavancin activity versus daptomycin and vancomycin against daptomycin-nonsusceptible Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic modelMolly E Steed, Céline Vidaillac, Michael J Rybak
The Journal of Antimicrobial Chemotherapy|August 16, 2014
Vancomycin plus ceftaroline shows potent in vitro synergy and was successfully utilized to clear persistent daptomycin-non-susceptible MRSA bacteraemiaKatie E Barber, Michael J Rybak, George Sakoulas
Pharmacotherapy|March 9, 2017
Role of Combination Antimicrobial Therapy for Vancomycin-Resistant Enterococcus faecium Infections: Review of the Current EvidenceJuwon Yim, Jordan R Smith, Michael J Rybak
The Journal of Antibiotics|October 14, 2010
A new assay to determine oritavancin concentrationsCéline Vidaillac, Jeffrey R Aeschlimann, Michael J Rybak
Pageof 54

Showing results (101-110 of 531) with videos related to

Sort By:
Pageof 54
Antimicrobial Agents and Chemotherapy|June 25, 2004
In vitro activities of a novel cephalosporin, CB-181963 (CAB-175), against methicillin-susceptible or -resistant Staphylococcus aureus and glycopeptide-intermediate susceptible staphylococciVanthida Huang, William J Brown, Michael J Rybak
Infection Control and Hospital Epidemiology|March 8, 2013
Comparative epidemiology of bacteremia due to methicillin-resistant Staphylococcus aureus between older and younger adults: a propensity score analysisRavina Kullar, Michael J Rybak, Keith S Kaye
Antimicrobial Agents and Chemotherapy|February 16, 2011
Impact of dose de-escalation and escalation on daptomycin's pharmacodynamics against clinical methicillin-resistant Staphylococcus aureus isolates in an in vitro modelCeline Vidaillac, Molly E Steed, Michael J Rybak
Antimicrobial Agents and Chemotherapy|October 6, 2010
Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetationsMolly E Steed, Celine Vidaillac, Michael J Rybak
International Journal of Antimicrobial Agents|March 30, 2010
In vitro evaluation of ceftaroline alone and in combination with tobramycin against hospital-acquired meticillin-resistant Staphylococcus aureus (HA-MRSA) isolatesCéline Vidaillac, Steve N Leonard, Michael J Rybak
Antimicrobial Agents and Chemotherapy|November 26, 2003
Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetationsRaymond Cha, William J Brown, Michael J Rybak
Antimicrobial Agents and Chemotherapy|November 30, 2011
Evaluation of telavancin activity versus daptomycin and vancomycin against daptomycin-nonsusceptible Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic modelMolly E Steed, Céline Vidaillac, Michael J Rybak
The Journal of Antimicrobial Chemotherapy|August 16, 2014
Vancomycin plus ceftaroline shows potent in vitro synergy and was successfully utilized to clear persistent daptomycin-non-susceptible MRSA bacteraemiaKatie E Barber, Michael J Rybak, George Sakoulas
Pharmacotherapy|March 9, 2017
Role of Combination Antimicrobial Therapy for Vancomycin-Resistant Enterococcus faecium Infections: Review of the Current EvidenceJuwon Yim, Jordan R Smith, Michael J Rybak
The Journal of Antibiotics|October 14, 2010
A new assay to determine oritavancin concentrationsCéline Vidaillac, Jeffrey R Aeschlimann, Michael J Rybak
Pageof 54